Научные статьи \ Прикладные науки. Медицина. Технология \ Mедицинские науки \ Патология. Клиническая медицина \ Заболевания пищеварительной системы. Болезнь пищеварительного тракта

Гипергомоцистеинемия и диабетическая нефропатия: влияние генетических факторов, клинико-патогенетические взаимосвязи с воспалением и анемией

Гипергомоцистеинемия и диабетическая нефропатия: влияние генетических факторов, клинико-патогенетические взаимосвязи с воспалением и анемией

Автор: Пчелин И.Ю., Гапешин Р.А., Худякова Н.В., Байрашева В.К.

Журнал: Juvenis scientia @jscientia

Рубрика: Медицинские науки

Статья в выпуске: 6, 2016 года.

Бесплатный доступ

В работе рассмотрены патогенетические факторы и клиническое значение гипергомоцистеинемии при диабетической нефропатии. Суммированы данные о влиянии полиморфизма гена метилентетрагидрофолатредуктазы на развитие и прогрессирование поражения почек при сахарном диабете. Проанализированы взаимосвязи гипергомоцистеинемии с провоспалительными цитокинами и анемией при диабетической нефропатии. Сформулированы направления дальнейших клинических исследований.

Гомоцистеин, метилентетрагидрофолатредуктаза, сахарный диабет, хроническая болезнь почек, диабетическая нефропатия, анемия, воспаление, полиморфизм

Короткий адрес: https://sciup.org/14110236

IDR: 14110236   |   УДК: 616.379-008.64:616.155.194

Hyperhomocysteinemia and diabetic nephropathy: the influence of genetic factors, clinical and pathogenic interrelations with inflammation and anemia

The article is focused on the pathogenic factors and clinical significance of hyperhomocysteinemia in patients with diabetic nephropathy. We summarize the data on the role of methylenetetrahydrofolate reductase gene polymorphism in the development and progression of diabetic kidney disease. The interrelationships between hyperhomocysteinemia, proinflammatory cytokines and anemia are analyzed. The directions of further clinical studies are proposed.

Список литературы Гипергомоцистеинемия и диабетическая нефропатия: влияние генетических факторов, клинико-патогенетические взаимосвязи с воспалением и анемией

  • Демидова Т. Ю. Сосудистые осложнения сахарного диабета 2 типа за гранью гликемического контроля//Сахарный диабет. 2010. № 3. С. 111-116.
  • Шестакова М. В., Шамхалова М. Ш., Ярек-Мартынова И. Я. и соавт. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения//Сахарный диабет. 2011. № 1. С. 81-88.
  • Худякова Н.В., Пчелин И.Ю., Шишкин А.Н., Иванов Н.В., Василькова О.Н. Гипергомоцистеинемия и кардиоренальный анемический синдром при сахарном диабете//Нефрология. 2015. Т. 19. №6. С. 20-27.
  • Cabarcapa V., Deric M., Stosic Z. et al. Determining the relationship between homocysteinemia and biomarkers of inflammation, oxidative stress and functional kidney status in patients with diabetic nephropathy//J. Med. Biochem. 2013. Vol. 32. P. 131-139.
  • Mudd S.H., Levy H.L., Kraus J. Disorders of Transsulfuration. In: Scriver C.R., Beaudet A.L., Sly W.S., Valle D., Childs B., Kinzler K., Vogelstein B., eds. The metabolic and molecular bases of inherited diseases//Mc Grow Hill. 2001. P. 2007-2056.
  • Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk//J. Appl. Genet. 2008. Vol. 49. № 3. P. 267-282.
  • Cacciapuotu F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties//J. Thromb. Thrombolysis. 2011. Vol. 32. P. 82-88.
  • Yilmaz N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases//Arch. Med. Sci. 2012. Vol. 8. № 1. P. 138-153.
  • Araki A., Hosoi T., Orimo H., Ito H. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes//Metabolism Clinical and Experimental. 2005. Vol. 54. P. 809-814.
  • Gojo Tomic N., Marusic S., Bozikov V. et al. The Relationship between Methylenetetrahydrofolate Reductase C677T Gene Polymorphism and Diabetic Nephropathy in Croatian Type 2 Diabetic Patients//Coll. Antropol. 2013. Vol. 37. № 3. P. 789-793.
  • Chwatko G., Jakubowski H. Urinary excretion of homocysteine-thiolactone in humans//Clin. Chem. 2005. Vol. 51. P. 408-415.
  • Yeh Y.-C., Huang M.-F., Hwang S.-J. et al. Association of homocysteine level and vascular burden and cognitive function in middle-aged and older adults with chronic kidney disease//Int. J. Geriatr. Psychiatry. 2015. Vol. 31. P. 723-730.
  • Kontoangelos K., Papageorgiou C., Raptis A. et al. Homocysteine, Cortisol, Diabetes Mellitus, and Psychopathology//J. Diabetes Res. 2015. P. 1-10.
  • Ndrepepa G., Kastrati A., Braun S. et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus//Nutrition, Metabolism and Cardiovascular Diseases. 2008. Vol. 18. P. 66-73.
  • Wang H., Cui K., Xu K., Xu S. Association between plasma homocysteine and progression of early nephropathy in type 2 diabetic patients//Int. J. Clin. Exp. Med. 2015. Vol. 8. № 7. P. 11174-11180.
  • Wollesen F., Brattstrom L., Refsum H. et al. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus//Kidney Int. 1999. Vol. 55. P. 1028-1035.
  • Mtiraoui N., Ezzidi I., Chaieb M. et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients//Diabetes Research and Clinical Practice. 2007. Vol. 75. P. 99-106.
  • Liew S.-C., Gupta E.D. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and the associated diseases//European Journal of Medical Genetics. 2015. Vol. 58. P. 1-10.
  • Monsalve M.V., Salzano F.M., Rupert J.L. et al. Methylenetetrahydrofolate Reductase (MTHFR) Allele Frequencies in Amerindians//Annals of Human Genetics. 2003. Vol. 67. P. 367-371.
  • Ukinc K., Ersoz H.O., Karahan C. et al. Methylentetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy//Endocrine. 2009. Vol. 36. P. 255-261.
  • Zhou T.-B., Drummen G., Jiang Z.-P. et al. Methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and diabetic nephropathy susceptibility in patients with type 2 diabetes mellitus//Renal Failure. 2015. Vol. 37. № 8. P. 1247-1259.
  • Brattstrom L., WiIcken D., Ohrvik J. et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis//Circulation. 1998. Vol. 98. P. 2520-2526.
  • Eldibany M.M., Caprini J.A. Hyperhomocysteinemia and thrombosis: an overview//Arch. Pathol. Lab. Med. 2007. Vol. 131. P. 872-884.
  • Zintzaras E., Uhlig K., Koukoulis G. et al. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis//J. Hum. Genet. 2007. Vol. 52. P. 881-890.
  • Soares A., Fernandes A., Cardoso J. et al. Plasma Total Homocysteine Levels and Methylenetetrahydrofolate Reductase Gene Polymorphism in Patients with Type 2 Diabetes Mellitus//Pathophysiol. Haemost. Thromb. 2009. Vol. 36. P. 275-281.
  • Boger C., Stubanus M., Haak T. et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy//Nephrol. Dial. Transplant. 2007. Vol. 22. P. 154-162.
  • Zsom M., Fulop T., Zsom L. et al. Genetic polymorphisms and the risk of progressive renal failure in elderly Hungarian patients//Hemodialysis International. 2011. Vol. 15. P. 501-508.
  • Hasegawa G., Obayashi H., Kamiuci K. et al. The Association Between End-Stage Diabetic Nephropathy and Methylenetetrahydrofolate Reductase Genotype with Macroangiopathy in Type 2 Diabetes Mellitus//Exp. Clin. Endocrinol. Diabetes. 2003. Vol. 111. P. 132-138.
  • El-Baz R., Settin A., Ismaeel A. et al. MTHFR C677T, A1298C and ACE I/D polymorphisms as risk factors for diabetic nephropathy among type 2 diabetic patients//Journal of Renin-Angiotensin-Aldosterone system. 2012. Vol. 13. № 4. P. 472-477.
  • Sun J., Xu Y., Zhu Y., Lu H. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients//Diabetes Research and Clinical Practice. 2004. Vol. 64. P. 185-190.
  • Ksiazek P., Bednarek-Skublewska A., Buraczynska M. The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus//Med. Sci. Monit. 2004. Vol. 10. № 2. P. 47-51.
  • Rahimi M., Hasanvand A., Rahimi Z. et al. Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro-and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus//Clinical Biochemistry. 2010. Vol. 43. P. 1333-1339.
  • Nemr R., Salman R., Jawad L. et al. Differential contribution of MTHFR C677T variant to the risk of diabetic nephropathy in Lebanese and Bahraini Arabs//Clin. Chem. Lab. Med. 2010. Vol. 48. № 8. P. 1091-1094.
  • El Hajj Chehadeh S., Jelinek H., Al Mahmeed W. et al. Relationship between MTHFR C677T and A1298C gene polymorphisms and complications of type 2 diabetes mellitus in an Emirati population//Meta Gene. 2016. Vol. 9. P. 70-75.
  • Jafari Y., Rahimi Z., Vaisi-Raygani A. et al. Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients//Mol. Cell. Biochem. 2011. Vol. 353. P. 23-34.
  • Movva S., Alluri R., Venkatasubramanian S. et al. Association of Methylene Tetrahydrofolate Reductase C677T Genotype With Type 2 Diabetes Mellitus Patients With and Without Renal Complications//Genetic Testing and Molecular Biomarkers. 2011. Vol. 15. № 4. P. 257-261.
  • Eroglu Z., Erdogan M., Tetik A. et al. The relationship of the methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy//Diabetes Metab. Res. Rev. 2007. Vol. 23. P. 621-624.
  • Maeda M., Yamamoto I., Fukuda M. et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients//Journal of Diabetes and Its Complications. 2008. Vol. 22. P. 119-125.
  • Baggott J.E, Tamura T. Homocysteine, iron and cardiovascular disease: a hypothesis//Nutrients. 2015. Vol. 7. P. 1108-1118.
  • Makhro A., Wang J., Vogel J. et al. Functional NMDA receptors in rat erythrocytes//Am. J. Physiol. Cell Physiol. 2010. Vol. 298. P. C1315-C1325.
  • Acharya U., Gau J. T., Horvath W. et al. Hemolysis and hyperhomocysteinemia caused by cobalamin deficiency: three case reports and review of the literature//J. Hematol. Oncol. 2008. Vol. 1. P. 26.
  • Пчелин И.Ю., Шишкин А.Н., Худякова Н.В., Василькова О.Н. Патогенетические факторы и клинические особенности анемии у пациентов с ранними стадиями диабетической нефропатии//Научный аспект. 2015. № 3. C. 258-270.
Еще
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp